Raymond James Financial Inc. bought a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 727,118 shares of the biotechnology company's stock, valued at approximately $3,628,000. Raymond James Financial Inc. owned 1.22% of Aldeyra Therapeutics as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of ALDX. Jacobs Levy Equity Management Inc. grew its holdings in Aldeyra Therapeutics by 163.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company's stock worth $2,571,000 after buying an additional 295,864 shares in the last quarter. Barclays PLC grew its stake in shares of Aldeyra Therapeutics by 280.1% in the 3rd quarter. Barclays PLC now owns 65,561 shares of the biotechnology company's stock worth $353,000 after acquiring an additional 48,313 shares in the last quarter. AlphaCentric Advisors LLC bought a new stake in shares of Aldeyra Therapeutics in the 4th quarter worth $234,000. PDT Partners LLC purchased a new stake in shares of Aldeyra Therapeutics in the third quarter valued at about $169,000. Finally, Boston Financial Mangement LLC bought a new position in shares of Aldeyra Therapeutics during the fourth quarter valued at about $141,000. 59.71% of the stock is currently owned by institutional investors.
Aldeyra Therapeutics Stock Performance
NASDAQ:ALDX traded down $0.92 during trading on Monday, reaching $5.75. The company's stock had a trading volume of 2,959,686 shares, compared to its average volume of 507,891. Aldeyra Therapeutics, Inc has a 12 month low of $3.10 and a 12 month high of $7.20. The firm has a 50 day moving average of $6.12 and a 200-day moving average of $5.51. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18.
Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.30). Equities analysts forecast that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Monday, March 3rd.
Get Our Latest Stock Report on Aldeyra Therapeutics
About Aldeyra Therapeutics
(
Free Report)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Further Reading
Before you consider Aldeyra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aldeyra Therapeutics wasn't on the list.
While Aldeyra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
